Principal Financial Group Inc. Has $4.23 Million Stake in Fortrea Holdings Inc. $FTRE

Posted by on Jul 29th, 2026

Principal Financial Group Inc. trimmed its holdings in shares of Fortrea Holdings Inc. (NASDAQ:FTRE – Free Report) by 7.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 449,081 shares of the company’s stock after selling 34,142 shares during the period. Principal Financial Group Inc. owned 0.47% of Fortrea worth $4,230,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of FTRE. Larson Financial Group LLC raised its position in shares of Fortrea by 136.7% during the 4th quarter. Larson Financial Group LLC now owns 1,856 shares of the company’s stock valued at $32,000 after acquiring an additional 1,072 shares during the last quarter. Osaic Holdings Inc. boosted its position in shares of Fortrea by 74.3% in the 2nd quarter. Osaic Holdings Inc. now owns 6,844 shares of the company’s stock worth $38,000 after purchasing an additional 2,918 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Fortrea by 137.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,713 shares of the company’s stock worth $43,000 after purchasing an additional 5,036 shares during the last quarter. Toronto Dominion Bank acquired a new stake in shares of Fortrea during the fourth quarter worth $51,000. Finally, Allworth Financial LP increased its holdings in Fortrea by 19.6% in the third quarter. Allworth Financial LP now owns 6,769 shares of the company’s stock valued at $57,000 after purchasing an additional 1,109 shares during the last quarter.

Fortrea Stock Performance

FTRE stock opened at $20.70 on Wednesday. Fortrea Holdings Inc. has a 1-year low of $5.26 and a 1-year high of $21.12. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 1.98. The firm has a market cap of $1.96 billion, a PE ratio of -4.22, a P/E/G ratio of 0.58 and a beta of 2.03. The business’s 50-day moving average price is $16.68 and its two-hundred day moving average price is $13.77.

Fortrea (NASDAQ:FTRE – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.13. Fortrea had a positive return on equity of 9.51% and a negative net margin of 16.50%.The company had revenue of $636.50 million during the quarter, compared to the consensus estimate of $628.50 million. As a group, research analysts forecast that Fortrea Holdings Inc. will post 0.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Mizuho increased their target price on Fortrea from $13.00 to $16.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. TD Cowen reaffirmed a “buy” rating on shares of Fortrea in a research note on Wednesday, May 6th. Truist Financial set a $19.00 price target on shares of Fortrea in a research report on Wednesday, May 6th. Robert W. Baird set a $20.00 price objective on shares of Fortrea in a research note on Wednesday, May 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Fortrea in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.75.

Get Our Latest Research Report on Fortrea

Fortrea Profile

(Free Report)

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.

Featured Stories

Want to see what other hedge funds are holding FTRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fortrea Holdings Inc. (NASDAQ:FTRE – Free Report).

Institutional Ownership by Quarter for Fortrea (NASDAQ:FTRE)

Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.